Strontium-Substituted Dicalcium Silicate Bone Cements with Enhanced Osteogenesis Potential for Orthopaedic...

Current bone cements face limitations in promoting bone regeneration and controlling resorption. While dicalcium silicate (C2S) cements are known for their bioactive properties, their biological performance remains suboptimal. Prior research has shown that strontium (Sr) can enhance bone formation and reduce resorption. However, integrating Sr into C2S cements has not been fully explored. This gap motivated the investigation of Sr-substituted C2S cements. No prior work had resolved how Sr incorporation affects cement properties and cell behavior. The need for improved bioactive materials in orthopaedics drives this research. Existing studies lack a comprehensive evaluation of Sr-substituted C2S in both mechanical and biological contexts. This paper addresses that uncertainty by testing Sr-substituted C2S cements. The study aims to bridge the gap between material design and biological outcomes.

The goal of this study was to evaluate the biological and mechanical properties of Sr-substituted dicalcium silicate (C2S) bone cements. The specific problem addressed is the need for bioactive materials that promote bone regeneration while maintaining structural integrity. The motivation stems from the known benefits of Sr in bone metabolism. The study tests whether Sr incorporation improves cement performance. The research focuses on assessing bioactivity, setting time, compressive strength, and cell response. The aim is to determine if Sr-substituted C2S cements are viable for orthopaedic use. The study also seeks to establish the optimal Sr concentration for enhanced performance. This work contributes to the development of next-generation bone cements.

The researchers used chemical co-precipitation to prepare Sr-substituted C2S powders with Sr concentrations ranging from 0.3% to 6.8%. X-ray diffraction (XRD) analysis was conducted to confirm Sr incorporation into the C2S lattice. The powders were mixed with water to form bone cements. Setting times were measured using standard methods. Compressive strength tests were performed to evaluate mechanical properties. Bioactivity was assessed by exposing cements to simulated body fluid (SBF) for seven days. Human bone marrow mesenchymal stem cells (hBMSCs) were cultured with the cements. Cell proliferation and alkaline phosphatase (ALP) activity were measured to assess biological performance.

XRD analysis confirmed Sr incorporation into the C2S lattice. Sr-C2S cements had a final setting time of 570 to 594 minutes. Compressive strength was higher than standard C2S cements in certain Sr concentration ranges. The cements induced apatite formation in SBF within seven days. hBMSC proliferation was significantly higher with Sr-C2S compared to standard C2S. ALP activity in hBMSCs was also elevated in Sr-C2S groups. These findings suggest enhanced bioactivity and osteogenic potential. The results support the use of Sr-substituted C2S for bone regeneration.

The study shows that Sr incorporation into C2S cements improves both mechanical and biological properties. The authors propose that Sr-C2S cements may serve as bioactive materials for orthopaedic applications. The observed apatite formation and enhanced hBMSC activity suggest improved osteogenesis. The compressive strength and setting time are within acceptable clinical ranges. The findings align with prior research on Sr’s role in bone regeneration. The results do not confirm Sr as essential for all applications but suggest it as beneficial. The authors highlight the potential of Sr-substituted C2S for future clinical use. The study does not claim broader implications beyond the tested parameters.